Neuroinflammation in Alzheimer's disease wanes with age

Journal of Neuroinflammation

Willem A van Gool²  Piet Eikelenboom²  Elise S van Haastert¹  Annemieke JM Rozemuller¹  Jeroen JM Hoozemans¹ 

[1] Department of Pathology, VU University Medical Center, P.O. Box 7057, 1007 MB Amsterdam, The Netherlands;Department of Neurology, Academic Medical Center, University of Amsterdam, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands

关键词: aging;    astrocyte;    microglia;    Alzheimer's disease;   

Others  :  1212973
DOI  :  10.1186/1742-2094-8-171

 received in 2011-10-11, accepted in 2011-12-07,  发布年份 2011

【 摘 要 】

Background

Inflammation is a prominent feature in Alzheimer's disease (AD). It has been proposed that aging has an effect on the function of inflammation in the brain, thereby contributing to the development of age-related diseases like AD. However, the age-dependent relationship between inflammation and clinical phenotype of AD has never been investigated.

Methods

In this study we have analysed features of the neuroinflammatory response in clinically and pathologically confirmed AD and control cases in relation to age (range 52-97 years). The mid-temporal cortex of 19 controls and 19 AD cases was assessed for the occurrence of microglia and astrocytes by immunohistochemistry using antibodies directed against CD68 (KP1), HLA class II (CR3/43) and glial fibrillary acidic protein (GFAP).

Results

By measuring the area density of immunoreactivity we found significantly more microglia and astrocytes in AD cases younger than 80 years compared to older AD patients. In addition, the presence of KP1, CR3/43 and GFAP decreases significantly with increasing age in AD.

Conclusion

Our data suggest that the association between neuroinflammation and AD is stronger in relatively young patients than in the oldest patients. This age-dependent relationship between inflammation and clinical phenotype of AD has implications for the interpretation of biomarkers and treatment of the disease.

【 授权许可】

   
2011 Hoozemans et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, et al.: Inflammation and Alzheimer's disease. Neurobiol Aging 2000, 21:383-421.
• [2]Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ: Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiol Aging 2000, 21:39-47.
• [3]Vehmas AK, Kawas CH, Stewart WF, Troncoso JC: Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 2003, 24:321-31.
• [4]Hoozemans JJ, Van Haastert ES, Veerhuis R, Arendt T, Scheper W, Eikelenboom P, Rozemuller AJ: Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. J Neuroinflammation 2005, 2:27. BioMed Central Full Text
• [5]Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, et al.: Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009, 41:1088-1093.
• [6]Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, et al.: Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 2009, 41:1094-1099.
• [7]Mrak RE, Griffin WST: Glia and their cytokines in progression of neurodegeneration. Neurobiology of Aging 2005, 26:349-354.
• [8]Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P: Soothing the inflamed brain: effect of non-steroidal anti-inflammatory drugs on Alzheimer's disease pathology. CNS Neurol Disord Drug Targets 2011, 10:57-67.
• [9]Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB: In-vivo measurement of activated microglia in dementia. Lancet 2001, 358:461-7.
• [10]Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R, Walker Z, Kennedy A, Fox N, Rossor M, et al.: Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009, 72:56-62.
• [11]Franceschi C, Bonafe M: Centenarians as a model for healthy aging. Biochem Soc Trans 2003, 31:457-461.
• [12]Streit WJ, Braak H, Xue QS, Bechmann I: Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease. Acta Neuropathol 2009, 118:475-485.
• [13]Reisberg B, Ferris SH, de Leon MJ, Crook T: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982, 139:1136-9.
• [14]Yamaguchi H, Haga C, Hirai S, Nakazato Y, Kosaka K: Distinctive, rapid, and easy labeling of diffuse plaques in the Alzheimer brains by a new methenamine silver stain. Acta Neuropathol (Berl) 1990, 79:569-72.
• [15]Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991, 82:239-259.
• [16]Vitek MP, Brown CM, Colton CA: APOE genotype-specific differences in the innate immune response. Neurobiol Aging 2009, 30:1350-1360.
• [17]Meyer MR, Tschanz JT, Norton MC, Welsh-Bohmer KA, Steffens DC, Wyse BW, Breitner JC: APOE genotype predicts when--not whether--one is predisposed to develop Alzheimer disease. Nat Genet 1998, 19:321-322.
• [18]Sheng JG, Mrak RE, Griffin WS: Enlarged and phagocytic, but not primed, interleukin-1 alpha-immunoreactive microglia increase with age in normal human brain. Acta Neuropathol 1998, 95:229-234.
• [19]Schuitemaker A, van der Doef TF, Boellaard R, van der Flier WM, Yaqub M, Windhorst AD, Barkhof F, Jonker C, Kloet RW, Lammertsma AA, et al.: Microglial activation in healthy aging. Neurobiol Aging 2010.
• [20]Beach TG, Walker R, McGeer EG: Patterns of gliosis in Alzheimer's disease and aging cerebrum. Glia 1989, 2:420-436.
• [21]Streit WJ: Microglia and neuroprotection: implications for Alzheimer's disease. Brain Res Brain Res Rev 2005, 48:234-239.
• [22]Pont-Lezica L, Bechade C, Belarif-Cantaut Y, Pascual O, Bessis A: Physiological roles of microglia during development. J Neurochem 2011, 119:901-908.
• [23]Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P: Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci 2006, 24:157-165.
• [24]Streit WJ, Sammons NW, Kuhns AJ, Sparks DL: Dystrophic microglia in the aging human brain. Glia 2004, 45:208-212.
• [25]Ramprasad MP, Terpstra V, Kondratenko N, Quehenberger O, Steinberg D: Cell surface expression of mouse macrosialin and human CD68 and their role as macrophage receptors for oxidized low density lipoprotein. Proc Natl Acad Sci USA 1996, 93:14833-14838.
• [26]Deininger MH, Pater S, Strik H, Meyermann R: Macrophage/microglial cell subpopulations in glioblastoma multiforme relapses are differentially altered by radiochemotherapy. J Neurooncol 2001, 55:141-147.
• [27]Caffo M, Caruso G, Germano A, Galatioto S, Meli F, Tomasello F: CD68 and CR3/43 immunohistochemical expression in secretory meningiomas. Neurosurgery 2005, 57:551-557.
• [28]Kim SU, de Vellis J: Microglia in health and disease. J Neurosci Res 2005, 81:302-313.
• [29]Colton CA, Wilcock DM: Assessing activation states in microglia. CNS Neurol Disord Drug Targets 2010, 9:174-191.
• [30]Wyss-Coray T, Mucke L: Inflammation in neurodegenerative disease--a double-edged sword. Neuron 2002, 35:419-32.
• [31]van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P: Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE varepsilon4 allele. Lancet Neurol 2011, 10:280-288.
• [32]van Gool WA, Aisen PS, Eikelenboom P: Anti-inflammatory therapy in Alzheimer's disease: is hope still alive? J Neurol 2003, 250:788-92.
• [33]Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C: Age, neuropathology, and dementia. N Engl J Med 2009, 360:2302-2309.
• [34]van Gool WA, Eikelenboom P: The two faces of Alzheimer's disease. J Neurol 2000, 247:500-505.